Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 12 September 2014 | By Louise Zornoza,
This content is provided by RegLink News, publishers of e-weekly global regulatory news. RegLink offers a 30-day free trial and 15% discount on Global Update subscriptions to RAPS members.
Australia’s Therapeutic Goods Administration (TGA) has announced (11 September) an internal reorganization as part of broader structural changes within the Department of Health following the Finance Ministry’s call for a "smaller and more rational" government.
The Drug Control Section, which is responsible for administering the regulations on internationally controlled drugs, has moved from the Department of Health’s Office of Chemical Safety (OCS) to the TGA’s Office of Scientific Evaluation. In addition, the Secretariat for the Advisory Committee on Medicines Scheduling (ACMS) has also moved to the TGA from the Department of Health.
Tags: Reorganization, Australian Finance Ministry, Australia
Regulatory Focus newsletters
All the biggest regulatory news and happenings.